Meta Information

ID:statins

Name:Statins

Schema Version:1.5

Title

Statin

Alternate Names

• HMG-CoA reductase inhibitors

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:

5

High Cost:

50

Cost Type:

monthly

Description:

Generic versions are widely available and highly affordable without insurance.

Summary

Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, which powerfully lowers LDL cholesterol (LDL-C). From a healthspan perspective, their primary benefit is the profound reduction in the risk of atherosclerotic cardiovascular disease (ASCVD), a leading cause of age-related mortality and morbidity. By preventing the buildup of arterial plaque, statins directly combat a central mechanism of aging-related vascular decline.

Purpose

Lowers LDL cholesterol to prevent atherosclerotic cardiovascular disease.

Card Summary

A class of drugs that lowers LDL cholesterol by inhibiting its production in the liver, primarily used to prevent cardiovascular disease.

Drug Class

Drugs In Class

• atorvastatin
• rosuvastatin
• simvastatin
• pravastatin
• lovastatin
• fluvastatin
• pitavastatin

Impact

Score:

8.5

Justification:

Dramatically reduces risk of ASCVD, a leading cause of age-related mortality.

Evidence

Grade:

A

Score:

10

Justification:

Vast body of evidence from numerous large-scale human RCTs and meta-analyses.

Safety

Score:

5.5

Justification:

Well-tolerated but associated with muscle pain and a small risk of diabetes.

Flags

• Requires a prescription and medical supervision.
• Common side effects include muscle pain (myalgia) and digestive issues.
• Associated with a small but statistically significant increased risk of developing type 2 diabetes.
• Interacts with grapefruit juice and certain drugs (e.g., macrolide antibiotics, azole antifungals).
• Individual response and side effect profiles vary between different statins.

Verdict

Foundational for ASCVD prevention if LDL-C is elevated or high-risk.

Created

2026-04-24T00:12:00.594852Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:

oral

Scope:

• systemic

Indication

Focus:

disease_treatment

Description:

Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, which powerfully lowers LDL cholesterol (LDL-C). From a healthspan perspective, their primary benefit is the profo...

Typical Protocol

• Low-dose daily administration (e.g., Rosuvastatin 5-10mg) is often used for primary prevention.